Rationale The involvement of metabotropic glutamate 5 (mGlu5) receptors has been suggested in the reinforcing effects of psychostimulants. However, little is known about the role of these receptors in psychostimulant withdrawal. Objectives The role of mGlu5 receptors was assessed in the anhedonic and somatic aspects of psychostimulant withdrawal. Methods Anhedonia was assessed with the discrete-trial current-intensity intracranial self-stimulation (ICSS) procedure after the termination of cocaine (180 mg kg Conclusions mGlu5 receptor null mutation attenuates the anhedonic and somatic effects of psychostimulant withdrawal. This attenuated withdrawal in mGluR5 −/− mice may result from the lack of drug-induced adaptations in mGlu5 receptor function that may occur in mGluR5 +/+ mice with chronic drug administration. Thus, these results suggest the involvement of mGlu5 receptors in psychostimulant dependence and the mediation of the anhedonic and somatic signs of psychostimulant withdrawal.
Introduction
The administration of drugs of abuse, including cocaine and nicotine, increases glutamatergic neurotransmission in brain structures implicated in the regulation of reward processes, such as the dorsal striatum (McKee and Meshul 2005; Perez de la Mora et al. 1991) , nucleus accumbens (NAc; Pierce et al. 1996; Reid et al. 2000; Saellstroem Baum et al. 2006; Smith et al. 1995) , and ventral tegmental area (VTA; Duffy 1995, 1998; Schilstrom et al. 2000) . Moreover, drug-induced adaptations in glutamatergic neurotransmission have been suggested to be involved in the development of drug dependence (Hao et al. 2010; Kalivas and Volkow 2005; Kenny and Markou 2004; Liechti and Markou 2008) .
Numerous studies have demonstrated a role for the mGlu5 receptor in the rewarding effects of several drugs of abuse. One of the first demonstrations of the involvement of the mGlu5 receptor in the reinforcing effects of drugs of abuse was from Chiamulera and colleagues (2001) , who demonstrated that mice lacking the mGlu5 receptor did not selfadminister cocaine or display cocaine-induced hyperlocomotion. After this original observation in knockout mice, the attenuating effects of mGlu5 receptor blockade on drug selfadministration have been demonstrated extensively with the use of the mGlu5 receptor antagonists 2-methyl-6-(phenylethynyl)-pyridine hydrochloride (MPEP) and 3-([2-methyl-4-thiazol]ethynyl)pyridine (MTEP) for cocaine (Backstrom and Hyytia 2006; Kenny et al. 2003 Kenny et al. , 2005 Kumaresan et al. 2009; Martin-Fardon et al. 2009; Paterson et al. 2003; Tessari et al. 2004) , nicotine (Bespalov et al. 2005; Liechti and Markou 2007; Paterson and Markou 2005; Tessari et al. 2004) , and ethanol (Backstrom et al. 2004; Cowen et al. 2005; Schroeder et al. 2005) in rats. Furthermore, consistent with the findings of Chiamulera and colleagues in mGlu5 receptor mutant mice, MPEP suppressed cocaine-and nicotine-induced hyperlocomotion (Herzig and Schmidt 2004; McGeehan et al. 2004; Tessari et al. 2004; Veeneman et al. 2010) .
Localization studies have indicated a high abundance of mGlu5 receptors in brain sites involved in reward processes, including the striatum and NAc (Lu et al. 1999; Shigemoto et al. 1993; Testa et al. 1994) , further supporting the involvement of mGlu5 receptors in brain reward function. Moderate to low expression levels of mGlu5 receptors were also identified in other brain regions, including the olfactory tubercle, hippocampus, neocortex, subthalamic nucleus, entopeduncular nucleus, globus pallidus, ventral pallidum, and substantia nigra (Lu et al. 1999; Shigemoto et al. 1993; Testa et al. 1994) .
Studies suggest an important role for the mGlu5 receptor in the reinforcing and hyperlocomotive effects of psychomotor stimulant compounds, but little is known about the potential function of these receptors in psychostimulant dependence and withdrawal, the focus of the present studies. One of the primary symptoms of nicotine and cocaine withdrawal syndromes in humans is depressed mood and anhedonia, with anhedonia defined as the inability to experience pleasure from rewarding stimuli (American Psychiatric Association 2000; Hughes 2007 ). Anhedonia can be assessed reliably and quantitatively in rodents using the intracranial selfstimulation (ICSS) procedure, in which the anhedonic depression-like mood is reflected by elevations in brain reward thresholds (Markou and Koob 1991) . Withdrawal from chronic nicotine administration elevated brain reward thresholds in C57BL/6J mice in the ICSS procedure (Johnson et al. 2008; Stoker et al. 2008) . Similarly, cocaine withdrawal elevated ICSS thresholds in C57BL/6J mice (Stoker and Markou 2011) . Studies that investigated the effect of mGlu5 receptor antagonism on ICSS thresholds during nicotine and cocaine withdrawal in rats using the mGlu5 receptor antagonist MPEP demonstrated elevations in ICSS thresholds in both drug-withdrawing and control rats (Harrison et al. 2002; Kenny et al. 2005; Liechti and Markou 2007) . These findings suggest that blockade of mGlu5 receptors negatively regulates brain reward function both under baseline conditions and during nicotine withdrawal, thereby exacerbating the anhedonic aspects of nicotine withdrawal.
The somatic signs of withdrawal occur in both humans and rodents after termination of chronic administration of nicotine and cocaine (American Psychiatric Association 2000). Nicotine withdrawal in humans results in various somatic signs, including bradycardia, gastrointestinal discomfort, nausea, headache, increased appetite, drowsiness, sweating, and dizziness (American Psychiatric Association 2000; Hughes et al. 1984; Shiffman 1979) . Somatic signs observed during nicotine withdrawal in mice include body shakes, head shakes, paw tremor, scratching, and grooming (Balerio et al. 2004; Damaj et al. 2003; Isola et al. 1999; Salas et al. 2004; Semenova et al. 2003; Stoker et al. 2008) . In rodents, these somatic signs of withdrawal are not observed after the cessation of cocaine administration (Watkins et al. 2000) . Antagonism of the mGlu5 receptor by MPEP administration exacerbated the somatic signs of nicotine withdrawal in rats (Liechti and Markou 2007) .
The present study assessed the effects of null mutation of the mGlu5 receptor on the anhedonic aspects of spontaneous withdrawal from nicotine and cocaine. The somatic aspects of nicotine withdrawal were also assessed. Nicotine and cocaine withdrawal was induced in mice null for the mGlu5 receptor (mGluR5 −/− ) and their wild-type counterparts (mGluR5 +/+ ) by the removal of osmotic minipumps that contained nicotine, cocaine, or saline. The anhedonic aspects of nicotine/saline and cocaine/saline withdrawal were subsequently assessed using the ICSS procedure, and the somatic signs of nicotine withdrawal were assessed using observational methods. In addition, ICSS thresholds were assessed after the precipitation of nicotine withdrawal by administering the nonselective nicotinic acetylcholine receptor (nAChR) antagonist mecamylamine in nicotine-dependent mice.
Materials and methods

Subjects
The mGlu5 receptor null line (Grm5tm1Rod) was generated as described previously (Jia et al. 1998 ). The null line was backcrossed to the C57BL/6J strain for at least 10 generations, and the breeders were kindly donated to our laboratory by Novartis Pharma, Switzerland. Knockout and wild-type littermates were bred in our laboratory from heterozygous breeding pairs. Upon weaning, the mice were maintained in groups of 2-4 until the electrode implantation surgery, after which the mice were housed individually. The subjects were 8-to 12-week-old males at the beginning of the experiments. The animals were housed in a humidityand temperature-controlled animal facility on a 12/12 h (lights off at 7:00 AM) reverse light/dark cycle with ad libitum access to food and water except during testing. Behavioral testing was conducted during the dark phase of the light/dark cycle (unless otherwise required by the experimental design). All experiments were in accordance with the guidelines of the American Association for the Accreditation of Laboratory Animal Care and the National Research Council's Guide for Care and Use of Laboratory Animals and were approved by the University of California San Diego Institutional Animal Care and Use Committee.
Drugs
Nicotine hydrogen tartrate (Sigma-Aldrich, St. Louis, MO, USA) dissolved in sterile 0.9% saline solution was infused through subcutaneous (s.c.) osmotic minipumps for 28 days (model 2004; Alzet, Palo Alto, CA, USA). Cocaine hydrochloride (National Institute on Drug Abuse, Bethesda, MD, USA) dissolved in saline was infused through intraperitoneal (i.p.) osmotic minipumps for 3 days (model 1003D; Alzet). Mecamylamine hydrochloride (Sigma-Aldrich) dissolved in saline was injected subcutaneously in a volume of 0.1 ml/10 g. All drug doses are reported as the salt, with the exception of nicotine, the doses of which are reported as the weight of the base because of conventions in the field.
Minipump and ICSS electrode implantation was performed using aseptic surgery techniques as described previously (Stoker et al. 2008; Stoker and Markou 2011) . Details about ICSS apparati, training and testing in the ICSS procedure, and the assessment of the somatic signs of nicotine withdrawal are also described in detail in these same reports.
Experimental design
Experiment 1: Effects of chronic cocaine administration and withdrawal on performance in the ICSS procedure in mGluR5 −/− and mGluR5 +/+ mice mGluR5 −/− (n=15) and mGluR5 +/+ (n=16) mice were prepared with stimulating electrodes in the lateral hypothalamus and trained in the ICSS procedure. After establishment of stable ICSS performance (defined as ≤10% variation in brain reward thresholds over three consecutive test sessions), the mice were prepared with 3-day i.p. minipumps that delivered saline or 180 mg kg −1 day −1 cocaine (salt) and tested once daily. ICSS thresholds and response latencies during cocaine administration and withdrawal are expressed as the percentage of the baseline value (5-day average before cocaine administration). After 72 h of cocaine/saline administration, the minipumps were removed, and the mice were tested in the ICSS procedure 3, 6, 8, 12, 24, 28, 48, 52, 72, 76, 96 , and 100 h after pump removal and once daily thereafter.
Experiment 2: Effects of chronic nicotine administration and nAChR antagonist-precipitated and spontaneous nicotine withdrawal on ICSS performance and somatic signs in mGluR5 −/− and mGluR5 +/+ mice Naive mGluR5 −/− (n=30) and mGluR5 +/+ (n=26) mice were prepared with stimulating electrodes in the lateral hypothalamus and trained in the ICSS procedure. After establishment of stable ICSS performance, the mice were prepared with 28-day s.c. minipumps that delivered saline or 40 mg kg
nicotine base and tested once daily. Mecamylamine hydrochloride was injected s.c. on days 9, 11, 13, and 15 of nicotine/saline exposure using a within-subjects Latin square design for the factor Dose (0, 1.5, 3, and 6 mg/kg, salt). Mice were tested in the ICSS procedure immediately after mecamylamine/saline injection. ICSS thresholds and response latencies after mecamylamine/saline administration are expressed as the percentage of the baseline values obtained on the previous day. The mice were habituated to the cylinders for somatic sign observations on days 25 and 27 of nicotine/ saline exposure. On day 29, the minipumps were removed, and the mice were tested in the ICSS procedure 3, 6, 8, 12, 16, 24, 28, 48, 52, 72, 76, 96 , and 100 h after pump removal. At 24 h post-pump removal, the ICSS session was followed by a 20-min observation of somatic signs.
Statistical analyses
All analyses were performed using the PASW 18 Statistical Package (SPSS, Chicago, IL, USA). The data were analyzed using appropriate two-and three-way analyses of variance (ANOVAs), with Genotype, Cocaine/Saline Exposure, and Nicotine/Saline Exposure as the between-subjects factors and Administration Day, Withdrawal Day, and Mecamylamine Dose as the within-subjects factors. Newman-Keuls post hoc analyses followed statistically significant interaction effects in the ANOVAs. (Table 1) . ICSS thresholds with chronic nicotine administration were combined for analysis (days 16+17, days 18+19, days 20+ 21, days 22+23, days 24+25, and days 26+27) to provide robust and reliable estimates of the effects of nicotine/saline administration. For ICSS withdrawal, data time-points of early withdrawal were also analyzed using the mean of two sequential time-points (3+6, 8+12, 24+28, 48+52, 72+76, and 96+100 h). For further analysis of the overall effect of cocaine/nicotine withdrawal on ICSS thresholds, the areaunder-the-curve (i.e., the sum of the thresholds of all withdrawal time-points) was analyzed by two-way ANOVA, with Genotype, Cocaine/Saline Exposure, and Nicotine/ Saline Exposure as the between-subjects factors.
Results
Experiment 1: effects of chronic cocaine administration and withdrawal on performance in the ICSS procedure in mGluR5 −/− and mGluR5 +/+ mice
Chronic cocaine administration
Chronic administration of cocaine did not lower brain reward thresholds (Fig. 1a) . While an ANOVA of the chronic cocaine/saline administration data detected a statistically significant Genotype × Cocaine/Saline Exposure × Administration Day interaction (F 2,54 =3.283, p< 0.05), the instability of thresholds at the 4 h post-pump implantation time-point was most likely the cause of this interaction effect. Post hoc analyses revealed that ICSS thresholds in cocaine-treated mGluR5 +/+ and saline-treated mGluR5 −/− mice were elevated compared with their respective counterparts 4 h after the surgical procedure. The latency to turn the wheel manipulandum remained unaffected during cocaine administration (data not shown).
Cocaine withdrawal
During early cocaine withdrawal, ICSS thresholds in mGluR5 +/+ and mGluR5 −/− mice were significantly elevated compared with their respective saline-withdrawing counterparts (Fig. 1b) removal. The attenuation of cocaine withdrawal in mGluR5 −/− mice was also demonstrated by the analysis of the area-under-the-curve (Fig. 1b, inset) , which yielded a significant Cocaine/Saline Exposure × Genotype interaction (F 1,27 =4.324, p<0.05) and a significant main effect of Genotype (F 1,27 =19.841, p<0.001). Post hoc analyses of the area-under-the-curve data revealed significant threshold elevations during cocaine withdrawal in mGluR5 +/+ mice compared with cocaine-withdrawing mGluR5 −/− mice (p< 0.05) and saline-treated mGluR5 +/+ mice (p<0.01). Thresholds in saline-withdrawing mGluR5 +/+ and mGluR5 −/− mice did not differ from each other at any time-point and were close to 100% of baseline. The latency to turn the wheel manipulandum remained unaffected during cocaine withdrawal (data not shown).
Experiment 2: effects of chronic nicotine administration and nAChR antagonist-precipitated and spontaneous nicotine withdrawal on ICSS performance and somatic signs in mGluR5 −/− and mGluR5 +/+ mice
Chronic nicotine administration
During chronic nicotine administration, ICSS thresholds in nicotine-treated mGluR5 +/+ and mGluR5 −/− mice did not differ significantly from their saline-treated counterparts (Fig. 2a) . A significant Genotype × Nicotine/Saline Exposure × Administration Day interaction was found (F 9,468 =1.903, p<0.05), but the post hoc analyses did not reveal significant differences in ICSS thresholds between the experimental groups at any time point. No other Fig. 1 Effects of chronic cocaine/saline administration and withdrawal on ICSS thresholds in mGluR5 −/− and mGluR5 +/+ mice. The data are expressed as a percentage of baseline thresholds (mean ± SEM). a Effects of chronic cocaine/saline administration (180 mg kg −1 day −1 , base, 3 days) on ICSS thresholds in mGluR5 −/− and mGluR5 +/+ mice. Asterisk indicates a significant difference between saline-and cocainetreated mGluR5 +/+ mice (*p<0.05). Pound sign indicates a significant difference between saline-and cocaine-treated mGluR5 −/− mice ( # p< 0.05). b Effects of cocaine/saline withdrawal on ICSS thresholds in mGluR5 −/− and mGluR5 +/+ mice. Asterisks (**p<0.01) indicate significant differences between cocaine-and saline-treated mGluR5 +/+ mice at a specific time-point using Newman-Keuls post hoc comparisons after a significant Genotype × Cocaine/Saline Exposure interaction effect. Thresholds in cocaine-withdrawing mGluR5 +/+ mice were significantly elevated compared with their saline-treated counterparts at 3-6, 8-12, 24-28, 48-52, and 120 h after pump removal (p<0.01). Pound signs ( # p<0.05, ## p<0.01) indicate significant differences between cocaine-treated mGluR5 +/+ and mGluR5 −/− mice at 3-6 h (p<0.01) and 8-12 h (p<0.05). Inset to B: area-under-the-curve calculated as the sum of threshold values 3-120 h post-pump removal. Newman-Keuls post hoc analyses after a significant Genotype × Nicotine/Saline Exposure interaction demonstrated a significant elevation of thresholds in cocaine-withdrawing mGluR5 +/+ mice compared with cocaine-withdrawing mGluR5 −/− mice (*p<0.05) and salinetreated mGluR5 +/+ mice (**p<0.01) statistically significant main or interaction effects were observed. The latency to turn the wheel manipulandum remained unaffected during nicotine administration (data not shown). −/− and mGluR5 +/+ mice. ANOVA indicated a significant Genotype × Nicotine/Saline Exposure × Administration Day interaction, but post hoc analyses did not reveal significant differences in ICSS thresholds between the experimental groups at any time point. b Effects of mecamylamine-precipitated nicotine/saline withdrawal on ICSS thresholds in mGluR5 −/− and mGluR5 +/+ mice. Asterisks (**p<0.01) indicate a significant main effect of Mecamylamine in an ANOVA. c Effects of spontaneous nicotine/saline withdrawal on ICSS thresholds in mGluR5 −/− and mGluR5 +/+ mice. Asterisks (*p<0.05 and **p<0.01) indicate significant differences between nicotine-and saline-treated mGluR5 +/+ mice at specific time-points with pre-planned comparisons after an ANOVA indicated a significant main effect of Nicotine/Saline Exposure ( ## p< 0.01). Nicotine-withdrawing mGluR5 +/+ mice exhibited elevated thresholds compared with saline-treated mGluR5 +/+ mice. Although no statistically significant difference was found between nicotinewithdrawing mGluR5 −/− mice and mGluR5 +/+ mice, thresholds in mGluR5 −/− mice did not differ significantly from thresholds in their saline-treated counterparts. Inset to C: area-under-the-curve calculated as the sum of threshold values exhibited 3-100 h post-pump removal. Asterisks indicate a significant elevation of the area-under-the-curve in nicotine-withdrawing mGluR5 +/+ mice compared with saline-treated controls (*p<0.05) with pre-planned analyses after an ANOVA revealed a significant main effect of Nicotine/Saline Exposure Mecamylamine-precipitated nicotine withdrawal Mecamylamine administration induced similar ICSS threshold elevations in nicotine-treated mGluR5 +/+ and mGluR5 −/− mice compared with their saline-treated counterparts (Fig. 2b) , reflected by significant main effects of Mecamylamine Dose (F 3,156 =6.093, p<0.01) and Nicotine/Saline Exposure (F 1,52 =26.625, p<0.001) and the absence of a significant main effect of Genotype and no Nicotine/Saline Exposure × Genotype × Mecamylamine Dose interaction, although no Mecamylamine Dose × Nicotine/Saline Exposure interaction was observed. Preplanned comparisons did not reveal significant differences in ICSS thresholds among experimental groups after administration of any mecamylamine dose. The latency to turn the wheel manipulandum remained unaffected during mecamylamine-precipitated nicotine withdrawal (data not shown).
Spontaneous nicotine withdrawal
ICSS thresholds were elevated in mGluR5 +/+ and mGluR5
mice, reflected by a significant main effect of Nicotine/Saline Exposure (F 1,52 =9.862, p<0.01; Fig. 2c ). The ANOVA did not reveal any significant interaction or main effects of Genotype or Withdrawal Day. Preplanned comparisons, however, demonstrated that ICSS thresholds were significantly elevated in nicotine-withdrawing mGluR5 +/+ mice on days 1, 3, and 4 post-pump removal (p<0.05) compared with the thresholds in saline-withdrawing mGluR5 +/+ mice, whereas the thresholds in nicotine-withdrawing mGluR5 −/− mice were not significantly different from the thresholds of their saline-withdrawing counterparts at any time-point. Nicotine withdrawal was also attenuated in mGluR5 −/− mice when the area-under-the-curve data were analyzed (Fig. 2c,  inset ), reflected by a significant main effect of Nicotine/Saline Exposure (F 1,52 =9.862, p<0.01), with no significant main effect of Genotype and no interaction. Pre-planned analyses indicated that only nicotine-withdrawing mGluR5 +/+ , and not mGluR5 −/− , mice had significantly elevated thresholds compared with thresholds of saline-treated controls (p<0.05). The latency to turn the wheel manipulandum remained unaffected during spontaneous nicotine withdrawal (data not shown). Increases in somatic signs seen in nicotine-withdrawing mGluR5 +/+ mice were absent in mGluR5 −/− mice (Fig. 3) , reflected by significant main effects of Genotype (F 1,52 = 6.686, p<0.01) and Nicotine/Saline Exposure (F 1,52 =4.049, p<0.05), although no significant Genotype × Nicotine/ Saline Exposure interaction was found. Preplanned comparisons revealed that nicotine-treated mGluR5 +/+ mice had a significantly higher number of somatic signs than salinetreated mGluR5 +/+ mice (p<0.05) and nicotine-treated mGluR5 −/− mice (p<0.01).
Discussion
During withdrawal from chronic cocaine administration, ICSS thresholds in mGluR5 +/+ , but not mGluR5 −/− , mice were significantly elevated compared with the thresholds of their respective saline-treated controls. Moreover, thresholds in cocaine-withdrawing mGluR5 −/− mice were significantly lower than the thresholds of cocaine-withdrawing mGluR5 +/+ mice. This pattern of results indicates an attenuation of the anhedonic aspects of cocaine withdrawal in mice null for the mGlu5 receptor. Furthermore, the cessation of chronic nicotine administration resulted in significant elevations in ICSS thresholds in mGluR5 +/+ mice, whereas thresholds in mGluR5 −/− mice were not significantly elevated compared with the thresholds of their saline-treated counterparts. The difference in ICSS thresholds between mGluR5 +/+ and mGluR5 −/− mice was markedly more pronounced during cocaine withdrawal than during nicotine withdrawal. During nicotine withdrawal, ICSS thresholds in mGluR5 +/+ mice were only moderately elevated, possibly not allowing for the detection of differences in thresholds between nicotine-withdrawing mGluR5 +/+ and mGluR5 −/− mice. In addition, the somatic signs of nicotine withdrawal were absent in mGluR5
mice, whereas increases in somatic signs characterized nicotine withdrawal in mGluR5 +/+ mice. Elevations in brain reward thresholds have previously been reported in C57BL/6J mice during withdrawal from chronic nicotine (Johnson et al. 2008; Stoker et al. 2008) and cocaine (Stoker and Markou 2011) administration and are well established in rats for cocaine (Baldo et al. 1999; Kokkinidis and McCarter 1990; Koob 1991, 1992) and nicotine (Cryan et al. 2003; Epping-Jordan et al. 1998; Kenny et al. 2003; Skjei and Markou 2003) withdrawal. The present study demonstrated an attenuation of ICSS threshold elevations during drug withdrawal in mice null for the mGlu5 receptor compared with wild-type mice. −/− and mGluR5 +/+ mice (**p<0.01) with pre-planned comparisons after significant main effects of Genotype (p<0.01) and Nicotine/Saline Exposure (p<0.05) in an ANOVA The attenuation of the aversive aspects of withdrawal in mGluR5 −/− mice was further supported by the lack of increases in somatic signs that characterized nicotine withdrawal in mGluR5 +/+ mice. In addition to the expression of the mGlu5 receptor in central brain sites (see Introduction section), the localization of this receptor has also been shown in the periphery (Young et al. 2007 ). The somatic signs observed during nicotine withdrawal are primarily peripherally mediated (Watkins et al. 2000 ; but see Malin et al. 1997) . Thus, the lack of mGlu5 receptors in the periphery may be responsible for the absence of somatic signs of nicotine withdrawal in mGluR5 −/− mice.
At first glance, the present finding may appear contradictory to previous results demonstrating that pharmacological antagonism of mGlu5 receptors in rats somewhat exacerbate brain reward thresholds during psychostimulant withdrawal (Harrison et al. 2002; Kenny et al. 2005; Liechti and Markou 2007) and increases the somatic signs of nicotine withdrawal (Liechti and Markou 2007) . However, the present findings in mGlu5 receptor knockout mice are entirely consistent with these previous pharmacological findings in outbred rats because both sets of findings suggest the involvement of these receptors in the development of psychostimulant withdrawal. That is, the lack of the receptor in the knockout mice prevented the development of psychostimulant dependence, reflected by an attenuation of the anhedonic and somatic aspects of drug withdrawal, whereas the presence of the receptors during drug exposure in the rats rendered these receptors more sensitive to blockade in the outbred rats.
Excessive activation of the circuits involved in the positive reinforcing effects of drugs of abuse induces neuroadaptations to prevent these systems from overactivation. These neuroadaptations induced by drug administration are hypothesized to lead to the negative affect induced by the absence of the drug (Koob and Le Moal 2008; Markou et al. 1998) . The lack of neuroadaptations in mGlu5 receptors in brain reward circuits in mGluR5 −/− mice during chronic drug administration may therefore have resulted in less development of drug dependence and consequently in the attenuation of the negative state of drug withdrawal compared with wild-type mice. These hypothesized effects are reflected by the attenuation of the threshold elevations in mGluR5 −/− mice compared with mGluR5 +/+ mice during cocaine and nicotine withdrawal and the attenuation of the somatic signs of nicotine withdrawal. In addition, the upregulation of other receptors may have occurred in mGluR5 −/− mice during development to compensate for the lack of the permissive role of mGlu5 receptor activation in reward processes in these mice. For example, mGlu1 and mGlu5 receptors belong to the same group of metabotropic glutamate receptors based on similarities in their molecular structure and physiological functions. Pharmacological antagonism of mGlu1 and mGlu5 receptors similarly decreased reinstatement of nicotine seeking in rats (Bespalov et al. 2005; Dravolina et al. 2007 (Chen et al. 2010) , nicotine or cocaine administration may have induced neuroadaptations that resulted in NMDA receptor upregulation in mGlu5 receptor knockout mice. NMDA receptors are positively coupled to mGlu5 receptors in rats (Awad et al. 2000; Pisani et al. 2001) , and studies have demonstrated increased NMDA receptor subunit expression during nicotine withdrawal in rats (Kenny et al. 2009; Wang et al. 2008) . Increased NMDA receptor function, therefore, may have been induced by the administration of nicotine and cocaine in constitutively mGlu5 receptor knockout mice to compensate for the lack of the excitatory control exerted by mGlu5 receptor activation. Previous studies demonstrating that blockade of mGlu5 receptors in healthy drug-naive subjects negatively regulates reward function and results in a mild anhedonic mood state (Harrison et al. 2002; Kenny et al. 2003; Liechti and Markou 2007 ) suggest a role for mGlu5 receptor function in the regulation of mood, which may have resulted in compensatory adaptations in mood-regulatory systems in mGluR5 −/− mice because of the chronic absence of mGlu5 receptors during the development of these mice. Consistent with this hypothesized role of mGlu5 receptors in affective regulation and the present findings, an antidepressant behavioral profile was seen in mGluR5 −/− mice and wildtype mice treated with of the mGlu5 receptor antagonists MPEP and MTEP in the tail suspension and forced swim tests (Belozertseva et al. 2007; Li et al. 2006; Palucha et al. 2005) . In summary, the present study demonstrated an attenuation of the anhedonic aspects of the cocaine withdrawal syndrome in mGlu5 receptor null mice compared with their wild-type counterparts. Furthermore, mGlu5 receptor null mice demonstrated a tendency toward an attenuation of the anhedonic aspects of the nicotine withdrawal syndrome. Increases in the somatic signs of nicotine withdrawal were also attenuated in mGlu5 receptor knockout mice. The attenuation of the aversive aspects of drug withdrawal in mGluR5 −/− mice may have resulted from the lack of adaptations in mGlu5 receptor function induced by the administration of cocaine and nicotine that may have occurred in mGluR5 +/+ mice. This lack of drug-induced adaptations in mGlu5 receptor function may have consequently resulted in an attenuation of the anhedonic aspects of the cocaine and nicotine withdrawal syndromes and an attenuation of the somatic signs of nicotine withdrawal. Thus, these results suggest the critical involvement of mGlu5 receptors in the development of nicotine and cocaine dependence and mediation of the anhedonic and somatic signs of drug withdrawal.
Interestingly, the chromosomal region 11q14, on which the GRM5 gene is located, has been linked to habitual smoking behavior (Bierut et al. 2004) . The findings of the present study may suggest that individuals with genetic variations in the mGlu5 receptor, resulting in decreased mGlu5 receptor-mediated neurotransmission, may be less sensitive to the reinforcing effects of nicotine and cocaine and the depressive-like symptoms of psychostimulant drug withdrawal.
